insights_auto
Pourquoi MVIR a-t-elle augmenté de 5,77%?
Approfondirchevron_right
MVIR:STO
Medivir
1,69 SEK
arrow_upward
+5,77%(+0,092) 1J
2 oct., 17:29:51 UTC+2 · SEK
search
Tous les symboles
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour MVIR...
Ouverture
1,71 SEK
Élevé
1,78 SEK
Faible
1,67 SEK
Cap. boursière
1,06 Md
Vol. moyen
1,88 M
Volume
2,72 M
+ haut sur 1 an
2,88 SEK
+ bas sur 1 an
0,34 SEK
BPA
-0,37 SEK
Actions en circulation
624,18 M
Nombre d'employés
6
Ouverture
1,71 SEK
Élevé
1,78 SEK
Faible
1,67 SEK
Cap. boursière
1,06 Md
Vol. moyen
1,88 M
Volume
2,72 M
+ haut sur 1 an
2,88 SEK
+ bas sur 1 an
0,34 SEK
BPA
-0,37 SEK
Actions en circulation
624,18 M
Nombre d'employés
6
Articles
Sources : Web et partenaires du secteur de l'information
www.marketscreener.com
·
il y a 17 heures
DNB Carnegie resumes commissioned coverage of Medivir, sees strengthened portfolio and financing
Profil
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
À propos de Medivir